减重手术加速康复方案实施后阿片类药物使用减少
该回顾性研究纳入1340例行腹腔镜Roux-en-Y胃旁路术或袖状胃切除术的患者,比较标准方案、常规使用布比卡因脂质体(LB)及ERABS/LB三种策略。结果显示ERABS/LB组总阿片类药物用量降至23.8 MEU,较pre-LB组下降59.5%,44.9%患者术后无需额外阿片类药物,住院时间和再入院率亦显著降低。
要点
- ERABS方案使术后阿片类药物用量较标准方案下降59.5%。
- ERABS/LB组44.9%患者术后无需额外阿片类药物。
- ERABS/LB组住院时间平均1.48天,再入院率降低3.74%。
核心结论
- 实施ERABS可显著减少减重术后阿片类药物使用、缩短住院时间并降低再入院率。
- ERABS的效果优于仅在原有方案中添加布比卡因脂质体。
研究设计与样本
- 共1340例患者,分为pre-LB组304例、LB组754例、ERABS/LB组282例。
- 术后阿片类药物转换为吗啡等效单位(MEU),疼痛评分、住院时间和30天结局采用t检验和Mann-Whitney U检验分析。
主要发现
- 总住院阿片类药物用量:pre-LB组58.6 MEU,LB组40.8 MEU,ERABS/LB组23.8 MEU(p=0.01)。
- ERABS/LB组MEU需求较pre-LB组下降59.5%(p<0.001)。
- ERABS/LB组44.9%患者在外科病房无需额外阿片类药物,pre-LB组为0%(p<0.001)。
- ERABS/LB组平均住院时间1.48天,pre-LB组1.54天(p=0.03)。
- ERABS/LB组再入院率总体降低3.74%(p=0.03)。
临床怎么用
- 在减重手术中推行ERABS方案可有效减少术后阿片类药物消耗。
- ERABS方案有助于缩短住院时间并降低再入院率。
- ERABS联合布比卡因脂质体使用可让近半数患者术后无需额外阿片类药物。
局限性
- 本研究为回顾性综述,非随机对照设计。
- 需更多研究评估不使用布比卡因脂质体时ERABS的真实效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enhanced recovery after surgery (ERAS) protocols have been extensively proven in lower gastrointestinal surgery to decrease postoperative physiologic stress and length of stay (LOS). ERAS in bariatric surgery (ERABS) varies immensely from each program with inconsistent results with a predominant goal of reducing LOS. Our focus in implementing enhanced recovery after bariatric surgery (ERABS) protocols is aimed at reducing postoperative pain and opioid use. METHODS: This is a retrospective review of patients who underwent laparoscopic Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (VSG) at a single high-volume center from June 2016 to October 2017. Patients on previous standard protocol were categorized into "Pre-Liposomal Bupivacaine (LB) group." After routine use of Exparel™, patients were grouped into "LB group." After ERABS protocol was initiated, patients were categorized into "ERABS/LB group." Postoperative opioids were converted to morphine equivalents units (MEU); pain scores, LOS, and 30-day outcomes were analyzed using combination of t test and Mann-Whitney U. RESULTS: A total of 1340 patients were included in the study: 304 patients in pre-LB group; 754 patients in LB group, and 282 patients in ERABS/LB group. Total hospital opioid use was 58.6 MEU in pre-LB, 40.8 MEU in LB, and 23.8 MEU in ERABS/LB (p = 0.01). ERABS/LB group found a 59.5% decline in MEU requirements compared to pre-LB (p < 0.001) and 44.9% of patients did not require any additional narcotics on the floor compared to 0% in pre-LB group (p < 0.001). ERABS/LB LOS was an average of 1.48 days compared to 1.54 days in pre-LB group (p = 0.03) with an overall decrease of 3.74% in readmission rates (p = 0.03). CONCLUSIONS: Implementation of ERABS significantly reduced postoperative opioid use, LOS, and readmissions. With ERABS, a more profound effect was observed than simply adding Exparel™ to preexisting protocols. Almost half of these patients did not require narcotics while recovering on the surgical floor. More studies are required to assess the true effect of ERABS without use of Exparel™.
引用
- Ma P, Lloyd A, McGrath M, et al. Reduction of opioid use after implementation of enhanced recovery after bariatric surgery (ERABS). Surg Endosc. 2019. PMID: 31342260. doi:10.1007/s00464-019-07006-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。